Abstract:Importance: Observational studies suggest that statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, may be associated with beneficial effects in many noncardiovascular diseases.Objective: To construct a weighted HMG-CoA reductase (HMGCR) gene genetic risk score (GRS) using variants in the HMGCR gene affecting low-density lipoprotein cholesterol as an instrumental variable for mendelian randomization analyses to test associations with candidate noncardiovascular phenotypes previously associated with statin use in observational studies.Design, Setting, and Participants: This cohort study included 53 385 unrelated adults of European ancestry with genome-wide genotypes available from BioVU (a practice-based biobank, used for discovery) and 30 444 unrelated adults with European ancestry available in the Electronic Medical Records and Genomics (eMERGE; a research consortium that conducts genetic research using electronic medical records, used for replication). The study was conducted from February 6, 2015, through April 31, 2019; data analysis was performed from August 26, 2019, through December 22, 2020.Interventions: An HMGCR GRS was calculated.Main Outcomes and Measures: The association between the HMGCR GRS and the presence or absence of 22 noncardiovascular phenotypes previously associated with statin use in clinical studies.Results: Of the 53 385 individuals in BioVU, 29 958 (56.1%) were women; mean (SD) age was 59.9 (15.6) years. The finding between the HMGCR GRS and the noncardiovascular phenotypes of interest in this cohort was significant only for type 2 diabetes. An HMGCR GRS equivalent to a 10-mg/dL decrease in the low-density lipoprotein cholesterol level was associated with an increased risk of type 2 diabetes (odds ratio [OR], 1.09; 95% CI, 1.04-1.15; P = 5.58 × 10-4). The HMGCR GRS was not associated with other phenotypes; the closest were increased risk of Parkinson disease (OR, 1.30; 95% CI, 1.07-1.58; P = .007) and kidney failure (OR, 1.18; 95% CI, 1.05-1.34; P = .008). Of the 30 444 individuals in eMERGE, 16 736 (55.0%) were women; mean (SD) age was 68.7 (15.4) years. The association between the HMGCR GRS and type 2 diabetes was replicated in this cohort (OR, 1.09; 95% CI, 1.01-1.17; P = .02); however, the HMGCR GRS was not associated with Parkinson disease (OR, 0.93; 95% CI, 0.75-1.16; P = .53) and kidney failure (OR, 1.18; 95% CI, 0.98-1.41; P = .08) in the eMERGE cohort.Conclusions and Relevance: A mendelian randomization approach using variants in the HMGCR gene replicated the association between statin use and increased type 2 diabetes risk but provided no strong evidence for pleiotropic effects of statin-induced decrease of the low-density lipoprotein cholesterol level on other diseases.

Adjusting for medication status in genome-wide association studies

A Genetic Analysis of Current Medication Use in the UK Biobank

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications

A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes

Design and quality control of large-scale two-sample Mendelian randomization studies

Accounting for multiple comparisons in a genome-wide association study (GWAS)

Bias from heritable confounding in Mendelian randomization studies

Genotype Imputation of MetabochipSNPs Using a Study‐Specific Reference Panel of ∼4,000 Haplotypes in African Americans from the Women's Health Initiative

Characterizing the genetic architecture of drug response using gene-context interaction methods

Accounting for heterogeneity due to environmental sources in meta-analysis of genome-wide association studies

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population

Powerful genome-wide design and robust statistical inference in two-sample summary-data Mendelian randomization

Reducing Information and Selection Bias in EHR-Linked Biobanks via Genetics-Informed Multiple Imputation and Sample Weighting

Improving GWAS performance in underrepresented groups by appropriate modeling of genetics, environment, and sociocultural factors

Exploring and accounting for genetically driven effect heterogeneity in Mendelian Randomization

Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator

Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug–Gene Interactions for Commonly Used Drugs

Pharmacogenomics of GLP-1 Receptor Agonists: A genome-wide analysis of observational data and large randomized controlled trials

Analyses of biomarker traits in diverse UK biobank participants identify associations missed by European-centric analysis strategies

Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases

Using Instruments for Selection to Adjust for Selection Bias in Mendelian Randomization